Sun sells two more US manufacturing plants
The facilities in Philadelphia, Pennsylvania, and Aurora, Illinois will be sold along with 15 drug products made at the sites under an agreement announced on Saturday.
Sun said the divestitures are part of an ongoing consolidation of its manufacturing operations in the US following the $4bn (€3.5bn) acquisition of fellow India-based drug producer Ranbaxy last year.
The firm added that: “Frontida has agreed to continue manufacturing certain products for Sun Pharma at these facilities on a contract basis for a predetermined period.
"It has also agreed to offer employment to all production, quality and administrative personnel at the sites” Sun added.
The firm did not respond to arequest for additional comment.
Plant sales
Sun’s last US facility divestiture was in December when it sold its liquids and semi-solids unit in Bryan, Ohio to Missouri-based Nostrum Laboratories.
Like the agreement with Frontida, the earlier accord saw Nostrum hire all staff at the plant and take on production of several Sun drugs.
Sun’s manufacturing network consolidation is also impacting plants on the other side of the Atlantic.
In April the firm confirmed it will close a Ranbaxy manufacturing facility in Cashel, Ireland by the end of the year.
